

May 9, 2019



## Dance Biopharm Appoints Kenneth B. Lee, Jr. to Board of Directors

*-Financial Matters Expert to Serve as Chair of Audit Committee*

SAN FRANCISCO--(BUSINESS WIRE)-- [Dance Biopharm Holdings, Inc.](#), a privately-held clinical stage biopharma company focused on the development of novel soft mist inhalable formulations of biologics for people living with chronic diseases, today announced the appointment of Kenneth B. Lee, Jr. to the board of directors. He will also serve as the chair of the audit committee of the board. Mr. Lee has more than 40 years of experience in advising biotechnology companies in all aspects of a company's financial life cycle from strategic fundraising to initial public offering and mergers and acquisitions.

"We are excited to welcome Ken to our board of directors, where his extensive experience in guiding life sciences companies through all aspects of their financial strategy, should prove invaluable," stated Anne Whitaker, Chief Executive Officer of Dance Biopharm. "As we advance the clinical development of our novel inhaled biologics to treat patients living with chronic diseases, we look forward to benefiting from his industry guidance and leadership."

"Dance Biopharm is aiming to transform the field of inhaled biologic therapies and I look forward to working closely with the experienced management team to grow Dance into a leading commercial stage company offering treatment options for patients with serious chronic diseases," said Kenneth Lee.

Kenneth Lee currently serves as a General Partner with Hatteras Venture Partners, a venture fund focused on healthcare and life sciences, which he joined in 2003, and where he is involved in deal sourcing, investment decisions and implementing exit strategies. Previously, he was President of A.M. Pappas & Associates, LLC, a venture development firm, which he joined following 29 years with Ernst & Young. At Ernst & Young, Kenneth co-founded the firm's national life sciences practice.

Mr. Lee is a nationally-recognized financial matters expert and has served on eight public life sciences company boards, including Abgenix, CV Therapeutics, Maxygen and OSI Pharmaceuticals. He previously served as Chairman of the Inspire Pharmaceuticals board until the company's sale to Merck in 2011. Ken currently serves on the boards of Aralez, Inc., Eyenovia and BioCryst Pharmaceuticals. He received his B.A. in Business Administration from Lenoir-Rhyne College and his MBA from the University of North Carolina at Chapel Hill.

### **About Dance Biopharm**

Dance Biopharm is a private company based in the San Francisco Bay Area focused on developing novel inhaled formulations of biologics to treat diabetes and other serious chronic diseases. The company began operations in 2010, and was founded by John Patton, Ph.D., who has over 25 years of experience developing numerous inhaled therapies including insulin. For more information, please visit <http://dancebiopharm.com>.

### **FORWARD-LOOKING STATEMENTS**

All statements other than statements of historical fact included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. We have based these forward-looking statements upon information available to management of Dance as of the date of this release and management's expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to our limited operating history, our ability to successfully develop product candidates, including Dance 501, the cost and uncertainty of obtaining regulatory approvals, our ability to bring product candidates, including Dance 501, to multiple markets and our ability to develop inhaled formulations of other medicines.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190509005357/en/>

Investors

Robert H. Uhl  
Managing Director  
Westwicke IR  
858-356-5932  
[Robert.uhl@westwicke.com](mailto:Robert.uhl@westwicke.com)

Media  
Jim Heins  
Senior Vice President  
Westwicke PR  
203-682-8251  
[james.heins@icrinc.com](mailto:james.heins@icrinc.com)

Source: Dance Biopharm Holdings, Inc.